腹腔镜与开腹远端胃切除术对局部进展期胃癌患者3年无病生存的影响:CLASS-01随机临床试验
这项在中国14个中心开展的非劣效、开放标签随机临床试验纳入1056例临床分期T2、T3或T4a且无粗大淋巴结或远处转移的胃癌患者,比较腹腔镜与开腹远端胃切除术联合D2淋巴结清扫的3年无病生存率。结果显示腹腔镜组3年无病生存率为76.5%,开腹组为77.8%,绝对差值为-1.3%(单侧97.5%CI -6.5%至∞),未跨越预设的非劣效界值-10%。3年总生存率和复发累积发生率两组间无显著差异。
要点
- 腹腔镜远端胃切除术对比开腹手术,3年无病生存率绝对差值为-1.3%,未跨越-10%的非劣效界值。
- 3年总生存率腹腔镜组83.1% vs 开腹组85.2%,调整HR 1.19(95%CI 0.87-1.64;P=0.28),无显著差异。
- 3年累积复发率腹腔镜组18.8% vs 开腹组16.5%,亚分布HR 1.15(95%CI 0.86-1.54;P=0.35),无显著差异。
核心结论
- 在术前临床分期为局部进展期胃癌的患者中,与开腹远端胃切除术相比,腹腔镜远端胃切除术在3年无病生存方面未产生劣效结果。
研究设计与样本
- 非劣效、开放标签、随机临床试验,在中国14个中心开展。
- 2012年9月至2014年12月共纳入1056例临床分期T2、T3或T4a且无粗大淋巴结或远处转移的胃癌患者。
- 按中心、年龄、肿瘤分期和组织学分层后,以1:1比例随机分配至腹腔镜远端胃切除术组(n=528)或开腹远端胃切除术组(n=528),均行D2淋巴结清扫。
- 主要终点为3年无病生存率,非劣效界值为-10%;次要终点为3年总生存率和复发模式,采用优效性检验。
- 1056例患者中1039例(98.4%;平均年龄56.2岁;女性313例[30.1%])接受了手术(腹腔镜组n=519 vs 开腹组n=520),999例(94.6%)完成研究;最终随访日期为2017年12月31日。
主要发现
- 3年无病生存率腹腔镜组为76.5%,开腹组为77.8%,绝对差值为-1.3%(单侧97.5%CI -6.5%至∞),未跨越预设的非劣效界值。
- 3年总生存率腹腔镜组83.1% vs 开腹组85.2%,调整HR为1.19(95%CI 0.87-1.64;P=0.28),两组间无显著差异。
- 3年期间累积复发发生率腹腔镜组18.8% vs 开腹组16.5%,亚分布HR为1.15(95%CI 0.86-1.54;P=0.35),两组间无显著差异。
关键数值与推荐
- 非劣效界值预设为-10%,用于比较腹腔镜远端胃切除术与开腹远端胃切除术的3年无病生存率。
- 3年无病生存率绝对差值为-1.3%,单侧97.5%CI为-6.5%至∞,未跨越-10%的非劣效界值。
- 3年总生存率调整HR为1.19(95%CI 0.87-1.64;P=0.28)。
- 3年累积复发亚分布HR为1.15(95%CI 0.86-1.54;P=0.35)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Laparoscopic distal gastrectomy is accepted as a more effective approach to conventional open distal gastrectomy for early-stage gastric cancer. However, efficacy for locally advanced gastric cancer remains uncertain. OBJECTIVE: To compare 3-year disease-free survival for patients with locally advanced gastric cancer after laparoscopic distal gastrectomy or open distal gastrectomy. DESIGN, SETTING, AND PATIENTS: The study was a noninferiority, open-label, randomized clinical trial at 14 centers in China. A total of 1056 eligible patients with clinical stage T2, T3, or T4a gastric cancer without bulky nodes or distant metastases were enrolled from September 2012 to December 2014. Final follow-up was on December 31, 2017. INTERVENTIONS: Participants were randomized in a 1:1 ratio after stratification by site, age, cancer stage, and histology to undergo either laparoscopic distal gastrectomy (n = 528) or open distal gastrectomy (n = 528) with D2 lymphadenectomy. MAIN OUTCOMES AND MEASURES: The primary end point was 3-year disease-free survival with a noninferiority margin of -10% to compare laparoscopic distal gastrectomy with open distal gastrectomy. Secondary end points of 3-year overall survival and recurrence patterns were tested for superiority. RESULTS: Among 1056 patients, 1039 (98.4%; mean age, 56.2 years; 313 [30.1%] women) had surgery (laparoscopic distal gastrectomy [n=519] vs open distal gastrectomy [n=520]), and 999 (94.6%) completed the study. Three-year disease-free survival rate was 76.5% in the laparoscopic distal gastrectomy group and 77.8% in the open distal gastrectomy group, absolute difference of -1.3% and a 1-sided 97.5% CI of -6.5% to ∞, not crossing the prespecified noninferiority margin. Three-year overall survival rate (laparoscopic distal gastrectomy vs open distal gastrectomy: 83.1% vs 85.2%; adjusted hazard ratio, 1.19; 95% CI, 0.87 to 1.64; P = .28) and cumulative incidence of recurrence over the 3-year period (laparoscopic distal gastrectomy vs open distal gastrectomy: 18.8% vs 16.5%; subhazard ratio, 1.15; 95% CI, 0.86 to 1.54; P = .35) did not significantly differ between laparoscopic distal gastrectomy and open distal gastrectomy groups. CONCLUSIONS AND RELEVANCE: Among patients with a preoperative clinical stage indicating locally advanced gastric cancer, laparoscopic distal gastrectomy, compared with open distal gastrectomy, did not result in inferior disease-free survival at 3 years. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01609309.
引用
- Yu J, Huang C, Sun Y, et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3-Year Disease-Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS-01 Randomized Clinical Trial. JAMA. 2019. PMID: 31135850. doi:10.1001/jama.2019.5359
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。